for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hikal Limited

HIKA.NS

Latest Trade

155.70INR

Change

4.50(+2.98%)

Volume

319,239

Today's Range

147.30

 - 

160.60

52 Week Range

140.10

 - 

187.75

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
151.20
Open
151.50
Volume
319,239
3M AVG Volume
2.34
Today's High
160.60
Today's Low
147.30
52 Week High
187.75
52 Week Low
140.10
Shares Out (MIL)
123.30
Market Cap (MIL)
19,197.93
Forward P/E
--
Dividend (Yield %)
0.77

Next Event

Q2 2020 Hikal Ltd Earnings Release

Latest Developments

More

India's Hikal Sept-Qtr Profit Rises

India's Hikal June-Qtr Profit Rises

India's Hikal Seeks Shareholders' Nod For Issue Of Bonus Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hikal Limited

Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients (APIs) and contract research activities. The Company offers pharmaceuticals and agrochemicals. Its segments include Crop Protection and Pharmaceuticals. It offers agrochemicals, including active ingredients, such as Ammonium dithiocarbamate, Amitrole Tech, Diuron Tech, Ethion Tech, Imazalil Tech, Isoproturon Tech, Meta chloro Aniline (MCA), Quinalphos Tech and Temephos Tech, and intermediates and specialty chemicals, such as Phenyl-2-(phenylthio)-phenyl carbamate, 4-(Benzyloxy) Aniline Hydrochloride, N-Benzylpiperidine-4-carboxaldehyde, 3-Chloroaniline and 4 Aminobenzylamine. Its APIs include Gabapentin, Pregabalin, Levetiracetam, Quetiapine Fumarate, Memantine Hydrochloride, Venlafaxine Hydrochloride and Donepezil Hydrochloride. The Company operates in geographical areas, including India, Europe, the United States, Canada and South East Asia.

Industry

Biotechnology & Drugs

Contact Info

Great Eastern Chambers

Sector 11, CBD-Belapur

+91.22.30973100

http://www.hikal.com/

Executive Leadership

Jai Hiremath

Executive Chairman of the Board, Managing Director

Sameer Hiremath

President, Joint Managing Director, Executive Director

Peter Nightingale

President of Acoris Research Ltd.

Sham V. Wahalekar

Senior Vice President - Finance, Compliance Officer, Company Secretary

Ravi Khadabadi

Vice President - Procurement

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

10.0K

2018

12.8K

2019

15.9K

2020(E)

18.6K
EPS (INR)

2017

5.520

2018

6.267

2019

8.360

2020(E)

10.223
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

BRIEF-Hikal Gets Shareholders' Nod For Reappointment Of Jai Hiremath As Chairman, MD

* GETS SHAREHOLDERS' NOD FOR REAPPOINTMENT OF JAI HIREMATH AS CHAIRMAN, MD

BRIEF-India's Hikal Ltd Dec-Qtr Profit Rises

* DEC QUARTER PROFIT 232.4 MILLION RUPEES VERSUS 138.3 MILLION RUPEES YEAR AGO

BRIEF-Hikal Seeks Shareholders' Nod For Re-Appointment Of Jai Hiremath As Chairman, MD

* SEEKS SHAREHOLDERS' NOD FOR RE-APPOINTMENT OF JAI HIREMATH AS CHAIRMAN & MD

BRIEF-India's Hikal Ltd Sept qtr profit falls

* Sept quarter net profit 153.3 million rupees versus profit 163.2 million rupees year ago

BRIEF-India's Hikal June-qtr profit rises

* June quarter profit 133.2 million rupees versus profit of 115.4 million rupees year ago

BRIEF-Hikal Dec-qtr profit rises

* Dec quarter net profit 132 million rupees versus profit 124.1 million rupees year ago

BRIEF-Hikal Ltd Sept qtr profit rises

* Hikal Ltd - sept quarter net profit 152.4 million rupees versus profit 48.2 million rupees year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up